

# THE LYBALVI® EQUATION

**FASTEST GROWING  
ORAL ATYPICAL  
ANTIPSYCHOTIC**  
by percent change for  
schizophrenia or  
bipolar I disorder\*

OLANZAPINE +  
SAMIDORPHAN =

**LYBALVI®**  
olanzapine and samidorphan  
5 mg/10 mg · 10 mg/10 mg · 15 mg/10 mg  
20 mg/10 mg tablets

**Rethink treatment for your patients living  
with schizophrenia or bipolar I disorder**

Actor portrayal.

## Indications

LYBALVI is indicated for the treatment of:

- Schizophrenia in adults
- Bipolar I disorder in adults
  - Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
  - Maintenance monotherapy treatment

## Important Safety Information

**Boxed Warning:** Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.

### Contraindications:

LYBALVI is contraindicated in patients who are using opioids or are undergoing acute opioid withdrawal. If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products.

\*Source: IQVIA Total Prescriptions (TRx) Data October 2021 – July 2022.<sup>1</sup>

**Schizophrenia:** LYBALVI TRx grew 1946% (from 96 to 1964). Market leader TRx decreased 5% (from 190,096 to 180,297).

**Bipolar I Disorder:** LYBALVI TRx grew 2306% (from 71 to 1708). Market leader TRx decreased 3% (from 401,517 to 389,199).

Analysis includes market basket of products that have an indication consistent with an FDA-approved indication for LYBALVI. This information is not intended to suggest clinical comparability of products and should not be seen as making a claim regarding safety or efficacy.

### LYBALVI CO-PAY SAVINGS PROGRAM

Commercially insured eligible patients may be able to save on co-pay costs. Terms and Conditions apply.



**LEARN MORE AT  
LYBALVIHCP.COM**

Please see additional Important Safety Information and the Brief Summary of full Prescribing Information, including Boxed Warning, on the following pages.

# Important Safety Information

**Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis**, including stroke, transient ischemia attack, and fatalities. See Boxed Warning.

**Precipitation of Severe Opioid Withdrawal in Patients who are Physiologically Dependent on Opioids**: LYBALVI can precipitate opioid withdrawal in patients who are dependent on opioids, which can lead to an opioid withdrawal syndrome, sometimes requiring hospitalization. LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Prior to initiating LYBALVI, there should be at least a 7-day opioid-free interval from last use of short-acting opioids, and at least a 14-day opioid-free interval from the last use of long-acting opioids. Explain the risks associated with precipitated withdrawal and the importance of giving an accurate account of last opioid use to patients and caregivers.

**Vulnerability to Life-Threatening Opioid Overdose**: Attempting to overcome opioid blockade with high or repeated doses of exogenous opioids could lead to life-threatening or fatal opioid intoxication, particularly if LYBALVI therapy is interrupted or discontinued subjecting the patient to high levels of unopposed opioid agonist as the samidorphan blockade wanes. Inform patients of the potential consequences of trying to overcome the opioid blockade and the serious risks of taking opioids concurrently with LYBALVI or while transitioning off LYBALVI. In emergency situations, if a LYBALVI-treated patient requires opioid treatment as part of anesthesia or analgesia, discontinue LYBALVI. Opioids should be administered by properly trained individual(s) and patient should be continuously monitored in a setting equipped and staffed for cardiopulmonary resuscitation. Patients with a history of chronic opioid use prior to treatment with LYBALVI may have decreased opioid tolerance if LYBALVI therapy is interrupted or discontinued. Advise patients that this decreased tolerance may increase the risk of opioid overdose if opioids are resumed at the previously tolerated dosage.

**Neuroleptic Malignant Syndrome**, a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation, intensive symptomatic treatment, and close monitoring.

**Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)**, a potentially fatal condition reported with exposure to olanzapine, a component of LYBALVI. Symptoms include a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. Discontinue if DRESS is suspected.

**Metabolic Changes**, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Any patient treated with LYBALVI should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required anti-diabetic treatment despite discontinuation of the suspect drug. Measure weight and assess fasting glucose and lipids when initiating LYBALVI and monitor periodically.

**Tardive Dyskinesia (TD)**: Risk of developing TD (a syndrome of potentially irreversible, involuntary, dyskinetic movements) and the likelihood it will become irreversible increases with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses, or after discontinuation. Given these considerations, LYBALVI should be prescribed in a manner that is most likely to reduce the risk of tardive dyskinesia. If signs and symptoms of TD appear, drug discontinuation should be considered.

**Orthostatic Hypotension and Syncope**: Monitor orthostatic vital signs in patients who are vulnerable to hypotension, patients with known cardiovascular disease, and patients with cerebrovascular disease.

**Falls**: LYBALVI may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls, and consequently, fractures or other injuries. Assess patients for risk when using LYBALVI.

**Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases)**: Perform complete blood counts in patients with a history of a clinically significant low white blood cell (WBC) count or history of leukopenia or neutropenia. Discontinue LYBALVI if clinically significant decline in WBC occurs in the absence of other causative factors.

**Dysphagia**: Use LYBALVI with caution in patients at risk for aspiration.

**Seizures**: Use LYBALVI with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

**Potential for Cognitive and Motor Impairment**: Because LYBALVI may cause somnolence, impair judgment, thinking, or motor skills, caution patients about operating hazardous machinery, including motor vehicles, until they are certain that LYBALVI does not affect them adversely.

**Body Temperature Dysregulation**: Use LYBALVI with caution in patients who may experience conditions that increase core body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

**Anticholinergic (Antimuscarinic) Effects**: Olanzapine, a component of LYBALVI, was associated with constipation, dry mouth, and tachycardia. Use LYBALVI with caution with other anticholinergic medications and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus or related conditions. In postmarketing experience, the risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications.

**Hyperprolactinemia**: LYBALVI elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

**Risks Associated with Combination Treatment with Lithium or Valproate**: If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for a description of the risks for these products.

**Most common adverse reactions** observed in clinical trials were:

- *Schizophrenia (LYBALVI)*: weight increased, somnolence, dry mouth, and headache
- *Bipolar I Disorder, Manic or Mixed Episodes (olanzapine)*: asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor
- *Bipolar I Disorder, Manic or Mixed Episodes, adjunct to Lithium or Valproate (olanzapine)*: dry mouth, dyspepsia, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia

**Concomitant Medication**: LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Concomitant use of LYBALVI is not recommended with strong CYP3A4 inducers, levodopa and dopamine agonists. Reduce dosage of LYBALVI when using with strong CYP1A2 inhibitors. Increase dosage of LYBALVI with CYP1A2 inducers. Use caution with diazepam, alcohol, other CNS acting drugs, or in patients receiving anticholinergic (antimuscarinic) medications. Monitor blood pressure and reduce dosage of antihypertensive drug in accordance with its approved product labeling.

**Pregnancy**: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with LYBALVI. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to LYBALVI during pregnancy.

**Renal Impairment**: LYBALVI is not recommended for patients with end-stage renal disease (eGFR of <15 mL/minute/1.73 m<sup>2</sup>).

**To report SUSPECTED ADVERSE REACTIONS, contact Alkermes at 1-888-235-8008 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**Please see the Brief Summary of full Prescribing Information, including Boxed Warning, for LYBALVI on the following pages.**

**References**: **1.** IQVIA TRx. [Estimate derived from the use of information under license from the following IQVIA information service: Source of Business for the period October 2021 – July 2022. IQVIA expressly reserves all rights, including rights of copying, distribution and republication.] **2.** LYBALVI [prescribing information]. Waltham, MA: Alkermes, Inc.; 2021.



## LYBALVI® (olanzapine and samidorphan) tablets, for oral use

### BRIEF SUMMARY OF PRESCRIBING INFORMATION

(For complete details, see full Prescribing Information)

#### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.

#### INDICATIONS AND USAGE

LYBALVI is indicated for the treatment of:

- Schizophrenia in adults
- Bipolar I disorder in adults
  - Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
  - Maintenance monotherapy treatment

#### CONTRAINDICATIONS

LYBALVI is contraindicated in patients:

- who are using opioids
- who are undergoing acute opioid withdrawal

If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products.

#### WARNINGS AND PRECAUTIONS

##### Increased Mortality in Elderly Patients with Dementia-Related Psychosis:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than in placebo-treated patients (3.5% vs 1.5%, respectively). Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.

**Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis:** Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse reactions in patients treated with olanzapine compared to patients treated with placebo. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.

##### Precipitation of Severe Opioid Withdrawal in Patients Who Are Physiologically Dependent on Opioids:

Samidorphan, an opioid antagonist that is a component of LYBALVI, can precipitate opioid withdrawal in patients who are dependent on opioids, which can lead to an opioid withdrawal syndrome, sometimes requiring hospitalization. Therefore, LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Prior to initiating LYBALVI, there should be at least a 7-day opioid-free interval from last use of short-acting opioids, and at least a 14-day opioid-free interval from the last use of long-acting opioids. Explain the risks associated with precipitated withdrawal and the importance of giving an accurate account of last opioid use to patients and caregivers.

##### Vulnerability to Life-Threatening Opioid Overdose

**Risk of Opioid Overdose from Attempts to Overcome Samidorphan Blockade:** LYBALVI contains samidorphan, an opioid antagonist. Attempting to overcome LYBALVI's opioid blockade with high or repeated doses of exogenous opioids (e.g., because of ineffective analgesia or opioid withdrawal symptoms) could lead to life-threatening or fatal opioid intoxication (e.g., respiratory arrest, circulatory collapse), particularly if LYBALVI therapy is interrupted or discontinued, subjecting the patient to high levels of unopposed opioid agonist as the samidorphan blockade wanes. Inform patients of the potential consequences of trying to overcome the opioid blockade and the serious risks of taking opioids concurrently with LYBALVI or while transitioning off LYBALVI.

In emergency situations, if a LYBALVI-treated patient requires opioid treatment as part of anesthesia or analgesia:

- Discontinue LYBALVI,
- Opioids should be administered by individual(s) trained in the use of anesthetic drugs and the management of the respiratory effects of opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation, and
- Appropriately trained personnel should continuously monitor the patient in a setting equipped and staffed for cardiopulmonary resuscitation.

For recommendations on starting opioids in LYBALVI-treated patients in non-emergent situations, see DRUG INTERACTIONS section.

##### Risk of Resuming Opioids in Patients with Prior Opioid Use

Patients with a history of chronic opioid use prior to treatment with LYBALVI may have decreased opioid tolerance if LYBALVI therapy is interrupted or discontinued. Advise patients that this decreased tolerance may increase the risk of opioid overdose if opioids are resumed at the previously tolerated dosage.

**Neuroleptic Malignant Syndrome:** Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, delirium, and autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

If NMS is suspected, immediately discontinue LYBALVI and provide intensive symptomatic treatment and monitoring.

**Drug Reaction with Eosinophilia and Systemic Symptoms:** Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with exposure to olanzapine, a component of LYBALVI. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue LYBALVI if DRESS is suspected.

**Metabolic Changes:** Atypical antipsychotic drugs, including LYBALVI, have been associated with metabolic changes that include hyperglycemia, diabetes mellitus, dyslipidemia, and body weight gain. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Any patient treated with LYBALVI should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with LYBALVI should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required anti-diabetic treatment despite discontinuation of the suspect drug. Patients starting treatment with LYBALVI should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.

Antipsychotics have caused adverse alterations in lipids. Patients starting treatment with LYBALVI should undergo fasting lipid profile testing at the beginning of treatment and periodically during treatment.

Weight gain has been observed with use of antipsychotics. Monitor weight prior to initiating LYBALVI and frequently thereafter.

**Tardive Dyskinesia:** Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk appears to be highest among the elderly, especially elderly women, but it is not possible to predict which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible increases with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses. It may also occur after discontinuation of treatment.

Tardive dyskinesia may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, LYBALVI should be prescribed in a manner that is most likely to reduce the risk of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients: 1) who suffer from a chronic illness that is known to respond to antipsychotic drugs; and 2) for whom alternative, effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. Periodically reassess the need for continued treatment.

If signs and symptoms of tardive dyskinesia appear in a patient on LYBALVI, drug discontinuation should be considered. However, some patients may require treatment with LYBALVI despite the presence of the syndrome.

**Orthostatic Hypotension and Syncope:** Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. In the 4-week, placebo-controlled study, from analysis of the vital signs data, rates of orthostatic hypotension were less than 2% in LYBALVI- and placebo-, and olanzapine-treated patients. In the 24-week, olanzapine-controlled study, from analysis of the vital signs data, rates of orthostatic hypotension in LYBALVI-treated patients were 3.7%, compared to 0.4% in olanzapine-treated patients.

Monitor orthostatic vital signs in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications or CNS depressants, patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients with cerebrovascular disease. LYBALVI has not been evaluated in patients with a recent history of myocardial infarction or unstable cardiovascular disease. Such patients were excluded from the premarketing clinical trials.

**Falls:** Antipsychotics, including LYBALVI, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

**Leukopenia, Neutropenia, and Agranulocytosis:** Leukopenia and neutropenia have been reported during treatment with antipsychotic agents, including LYBALVI. Agranulocytosis (including fatal cases) has been reported with other agents in this class.

Possible risk factors for leukopenia and neutropenia include pre-existing low white blood cell count (WBC) or absolute neutrophil count (ANC) and history of drug-induced leukopenia or neutropenia. In patients with a pre-existing low WBC or ANC or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of LYBALVI at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue LYBALVI in patients with severe neutropenia (absolute neutrophil count <1000/mm<sup>3</sup>) and follow their WBC until recovery.

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, including LYBALVI, should be used cautiously in patients at risk for aspiration.

**Seizures:** Like other antipsychotic drugs, LYBALVI may cause seizures. This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in older patients.

**Potential for Cognitive and Motor Impairment:** LYBALVI, like other antipsychotics, may cause somnolence and has the potential to impair judgment, thinking, or motor skills. In a LYBALVI placebo-controlled study, somnolence occurred in 9% of LYBALVI-treated patients compared to 2.2% in patients treated with placebo.

Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that LYBALVI therapy does not affect them adversely.

**Body Temperature Dysregulation:** Atypical antipsychotics may disrupt the body's ability to reduce core body temperature. Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use LYBALVI with caution in patients who may experience these conditions.

**Anticholinergic (Antimuscarinic) Effects:** Olanzapine, a component of LYBALVI, exhibits in vitro muscarinic receptor affinity. In premarketing clinical trials with oral olanzapine, olanzapine was associated with constipation, dry mouth, and tachycardia, all adverse reactions possibly related to cholinergic antagonism. Such adverse reactions were not often the basis for discontinuations, but LYBALVI should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, constipation, or a history of paralytic ileus or related conditions. In postmarketing experience, the risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications.

**Hyperprolactinemia:** As with other drugs that antagonize dopamine D<sub>2</sub> receptors, olanzapine, a component of LYBALVI, elevates prolactin levels, and the elevation can persist during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

In the 4-week placebo-controlled trial, shifts from normal to high prolactin values (>30 ng/mL for females; >20 ng/mL for males) occurred in 41.4% of females and 32.9% of males treated with LYBALVI, in 56.1% of females and 37.1% of males treated with olanzapine, and in 10% of females and 4.8% of males treated with placebo.

In the 24-week, olanzapine-controlled study, shifts from normal to high prolactin values occurred in 32.9% of females and 22.5% of males treated with LYBALVI, and in 41.7% of females and 28.5% of males treated with olanzapine.

**Risks Associated with Combination Treatment with Lithium or Valproate:**

If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for a description of the risks for these products including, but not limited to, the warnings and precautions for lithium or valproate.

**ADVERSE REACTIONS**

**Clinical Studies Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

**Adverse Reactions in Patients with Schizophrenia:**

*Patient Exposure*

The safety of LYBALVI was evaluated in 1262 patients (18 to 67 years of age) diagnosed with schizophrenia in four double-blind, controlled studies and three long-term safety extension studies of up to 3 years of duration. This experience corresponds to approximately 910 person-years. In these studies, there were a total of 663 patients exposed to LYBALVI for at least 6 months, and 386 patients for at least one year.

*Adverse Reactions in the Short-Term (4 week) Placebo-Controlled Trial in Adults with Schizophrenia*

The most common adverse reactions (incidence of at least 5% of patients exposed to LYBALVI and greater than twice the rate of placebo) are weight increased, somnolence, dry mouth, and headache.

Adverse reactions associated with the use of LYBALVI (incidence of 2% or greater and greater than in placebo-treated patients) are shown in Table 1.

**Table 1: Adverse Reactions Reported in ≥2% of LYBALVI-Treated Patients and Greater than Placebo in a 4-Week Schizophrenia Trial**

Adverse Reaction	Placebo (N=134) %	LYBALVI (10 mg/10 mg, 20 mg/10 mg) (N=134) %
Weight increased	3	19
Somnolence	2	9
Dry mouth	1	7
Headache	3	6
Blood insulin increased	1	3
Sedation	0	2
Dizziness	1	2
Neutrophil count decreased	0	2

Adverse reactions that led to discontinuation in LYBALVI-treated patients in the short-term placebo-controlled trial in adults with schizophrenia include schizophrenia (1%) and abnormal liver function tests (1%).

*Adverse Reactions in the Long-Term (24-week), Active-Controlled Trial in Adults with Schizophrenia*

In the 24-week, olanzapine-controlled trial in patients with stable schizophrenia, adverse reactions associated with the use of LYBALVI (incidence of 2% or greater) include: weight increased (25%), somnolence (21%), dry mouth (13%), increased appetite (11%), waist circumference increased (6%), blood creatine phosphokinase increased (5%), headache (4%), lethargy (4%), sedation (4%), akathisia (3%), alanine aminotransferase increased (3%), aspartate aminotransferase increased (3%), constipation (3%), dizziness (3%), fatigue (3%), nausea (3%), blood pressure increased (3%), neutrophil count decreased (3%), blood insulin increased (2%), weight decreased (2%), and dyslipidemia (2%).

Adverse reactions that led to LYBALVI treatment discontinuation in more than one patient include somnolence (2%), weight increased (2%), neutropenia (2%), glycosylated hemoglobin increased (1%), schizophrenia (1%), and liver function test abnormal (1%).

**Hyperglycemia:** Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of

the 2 highest serum concentrations was 15.0 mg/dL. Hyperglycemia, as defined by fasting glucose  $\geq 126$  mg/dL, has been observed in patients treated with LYBALVI.

In the 4-week placebo-controlled trial in adult patients with schizophrenia, shifts in fasting glucose from normal to high occurred in 4% of patients treated with LYBALVI, 1% of patients treated with olanzapine, and no patients treated with placebo.

In the 24-week olanzapine-controlled trial, patients treated with LYBALVI were more likely to experience abnormal shifts in glycemic parameters than patients treated with olanzapine (Table 2).

**Table 2: Changes in Glycemic Parameters in a 24-Week Trial of Patients with Schizophrenia**

	LYBALVI	Olanzapine
<b>Proportion of Patients with Shifts, % (n/N)*</b>		
Glucose Normal (<100 mg/dL to $\geq 126$ mg/dL)	12 (26/223)	8 (18/219)
Impaired ( $\geq 100$ mg/dL and <126 mg/dL) to High ( $\geq 126$ mg/dL)	24 (9/38)	11 (5/47)
Increase $\geq 10$ mg/dL	66 (174/265)	57 (154/270)
Hemoglobin A1c Normal (<5.7%) to Impaired ( $\geq 5.7\%$ and <6.5%)	42 (86/204)	35 (68/197)
Normal to High (<5.7% to $\geq 6.5\%$ )	0.5 (1/204)	1.5 (3/197)
Impaired ( $\geq 5.7\%$ and <6.5%) to High ( $\geq 6.5\%$ )	9.5 (6/63)	9.2 (7/76)

\* n: number of patients with reported abnormal shifts; N: number of patients who had assessments at both baseline and endpoint for mean change, or normal at baseline and at least 1 post-baseline assessment for shift.

**Dyslipidemia:** In the 4-week, placebo-controlled trial in adult patients with schizophrenia, shifts in fasting triglycerides from normal to high occurred in 14% of patients treated with LYBALVI and 4% of patients treated with placebo.

In the 24-week olanzapine-controlled study, mean changes in fasting total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were similar in patients treated with LYBALVI and in patients treated with olanzapine.

**Weight Gain:** In the 4-week placebo-controlled study in adult patients with schizophrenia, mean changes in weight, and proportion of patients with  $\geq 7\%$  weight increase, were greater in patients treated with LYBALVI and olanzapine than in patients on placebo. In that study, mean weight gain was 3.0 kg in patients treated with LYBALVI, 2.4 kg in patients treated with olanzapine, and 0.2 kg in patients treated with placebo. The proportion of patients with  $\geq 7\%$  weight increase was 26% in patients treated with LYBALVI, 20% in patients treated with olanzapine, and 5% in patients treated with placebo.

In the 24-week trial, LYBALVI-treated patients gained on average 4.2% of baseline body weight. The proportion of patients treated with LYBALVI with  $\geq 10\%$  body weight gain was 17.8%.

**Extrapyramidal Symptoms:** In the 4-week placebo-controlled trial in adult patients with schizophrenia, patients were assessed using the Simpson-Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS) (total score ranges from 1 to 14), the Barnes Akathisia Rating Scale (BARS) for akathisia (total score ranges from 0 to 14), and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias (total score ranges from 0 to 28). The mean changes from baseline to last study visit for the SAS, BARS, and AIMS was similar in LYBALVI-treated patients and in placebo-treated patients. The mean changes for LYBALVI- vs placebo-treated patients were 0.00 vs -0.2 for AIMS, 0.0 vs -0.1 for BARS, and 0.0 vs -0.3 for SAS, respectively. The rate of parkinsonism (SAS total score  $> 3$ ) was lower in patients treated with LYBALVI (4%) compared to those on placebo (10%). The rates of akathisia (BARS global clinical assessment score  $\geq 2$ ) and dyskinesia (AIMS score  $\geq 3$  on any of the first 7 items, or a score  $\geq 2$  on two or more of any of the first 7 items) were similar in patients treated with LYBALVI and in those on placebo. Rates of akathisia were 6.0% and 8.2% in patients treated with LYBALVI and placebo, respectively, and the rate of dyskinesia was 1.5% both in LYBALVI-treated and in placebo-treated patients.

The frequency of reported adverse reactions related to extrapyramidal symptoms, including akathisia, restlessness, muscle spasms, bradykinesia, tremor, extrapyramidal disorder, and parkinsonism was 2% both in LYBALVI-treated and in placebo-treated patients.

In the 24-week active-controlled trial, the mean change from baseline to the last visit for the SAS, BARS, and AIMS was similar in LYBALVI-treated patients and in those treated with the active control. Extrapyramidal adverse reactions, including parkinsonism, akathisia, and dyskinesia, had a similar incidence in LYBALVI-treated

patients and in those treated with the active control: any extrapyramidal symptom was 8%, akathisia was 3%.

**Dystonia:** Symptoms of dystonia, (prolonged abnormal contractions of muscle groups) may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. Although these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

**Adverse Reactions in Patients with Bipolar Disorder:** The safety of LYBALVI for the treatment of bipolar I disorder (mixed or manic) monotherapy and adjunct to lithium or valproate relies on information from adequate and well-controlled studies of olanzapine tablets in bipolar I disorder.

The most common adverse reactions (incidence of at least 5% of patients exposed to olanzapine and greater than or equal to twice the rate of placebo) from short-term trials of olanzapine (manic or mixed episodes) are somnolence, dry mouth, dizziness, asthenia, constipation, dyspepsia, increased appetite, and tremor.

The most common adverse reactions (incidence of at least 5% of patients exposed to olanzapine and greater than or equal to twice the rate of placebo) from short-term trials of olanzapine as adjunct to lithium or valproate (manic or mixed episodes) are dry mouth, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia.

**Postmarketing Experience:** The following adverse reactions have been identified during post-approval use of olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.

- allergic reactions (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria)
- cholestatic or mixed liver injury, hepatitis, jaundice
- diabetic coma, diabetic ketoacidosis
- discontinuation reaction (diaphoresis, nausea or vomiting)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- hyperlipidemia (random cholesterol levels of  $\geq 240$  mg/dL and random triglyceride levels of  $\geq 1000$  mg/dL have been reported)
- neutropenia
- pancreatitis
- priapism
- rash
- restless legs syndrome
- rhabdomyolysis
- salivary hypersecretion
- stuttering<sup>1</sup>
- venous thromboembolic events (including pulmonary embolism and deep venous thrombosis)

<sup>1</sup> Stuttering was only studied in oral and long-acting injection (LAI) formulations.

## DRUG INTERACTIONS

**Effects of Other Drugs on LYBALVI:** Table 3 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI.

**Table 3: Effects of Other Drugs on LYBALVI**

<b>Strong CYP3A4 Inducer</b>	
<i>Clinical Implication:</i>	Coadministration of LYBALVI with a strong CYP3A4 inducer decreases $AUC_{0-24}$ of olanzapine and samidorphan which may reduce LYBALVI efficacy.
<i>Prevention or Management:</i>	Concomitant use of LYBALVI with strong CYP3A4 inducers is not recommended.
<b>Strong CYP1A2 Inhibitor</b>	
<i>Clinical Implication:</i>	Concomitant use of LYBALVI with a strong CYP1A2 inhibitor increases olanzapine AUC and $C_{max}$ , which may increase risk of LYBALVI adverse reactions.
<i>Prevention or Management:</i>	Consider reducing the dosage of the olanzapine component in LYBALVI when used concomitantly with strong CYP1A2 inhibitors.
<b>CYP1A2 Inducer</b>	
<i>Clinical Implication:</i>	Concomitant use of LYBALVI with CYP1A2 inducers decreases olanzapine exposure, which may reduce LYBALVI efficacy.

**Table 3: Effects of Other Drugs on LYBALVI (cont'd)**

<i>Prevention or Management:</i>	Consider increasing the dosage of the olanzapine component in LYBALVI when used concomitantly with CYP1A2 inducers.
<b>Diazepam, Alcohol and CNS Acting Drugs</b>	
<i>Clinical Implication:</i>	Concomitant use of diazepam, alcohol, or other CNS acting drugs with LYBALVI may potentiate orthostatic hypotension observed with olanzapine.
<i>Prevention or Management:</i>	LYBALVI should be used with caution in patients receiving concomitantly diazepam or other CNS acting drugs, or using alcohol.
<b>Anticholinergic Drugs</b>	
<i>Clinical Implication:</i>	Concomitant treatment with olanzapine and other drugs with anticholinergic activity can increase the risk for severe gastrointestinal adverse reactions related to hypomotility.
<i>Prevention or Management:</i>	Consider increasing the dosage of the olanzapine component in LYBALVI when used concomitantly with CYP1A2 inducers.

**Effects of LYBALVI on Other Drugs:** Table 4 describes clinically significant drug interactions where concomitant use of LYBALVI affects other drugs.

**Table 4: Effects of LYBALVI on Other Drugs**

<b>Antihypertensive Agents</b>	
<i>Clinical Implication:</i>	LYBALVI may enhance the effects of certain antihypertensive agents.
<i>Prevention or Management:</i>	Monitor blood pressure and reduce dosage of antihypertensive drug in accordance with its approved product labeling.
<b>Levodopa and Dopamine Agonists</b>	
<i>Clinical Implication:</i>	LYBALVI may antagonize the effects of levodopa and dopamine agonists.
<i>Prevention or Management:</i>	Concomitant use of LYBALVI is not recommended with levodopa and dopamine agonists.

**Opioids:** LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal.

LYBALVI increases the risk of precipitating acute opioid withdrawal in patients who are dependent on opioids. Prior to initiating LYBALVI, there should be at least a 7-day opioid-free interval from the last use of short-acting opioids, and at least a 14-day opioid-free interval from the last use of long-acting opioids.

In *emergency* situations, if a LYBALVI-treated patient requires opioid treatment for anesthesia or analgesia, discontinue LYBALVI. The opioid should be administered by properly trained individual(s), and the patient should be properly monitored in a setting equipped and staffed for cardiopulmonary resuscitation.

In *non-emergency* situations, if a LYBALVI-treated patient is expected to require opioid treatment (e.g., for analgesia during or after an elective surgical procedure) discontinue LYBALVI at least 5 days before opioid treatment and start olanzapine or another antipsychotic, if needed.

Given that LYBALVI contains samidorphan, an opioid antagonist, opioid treatment may be less effective or ineffective shortly after LYBALVI discontinuation because of the presence of samidorphan.

#### USE IN SPECIFIC POPULATIONS

##### Pregnancy

**Pregnancy Exposure Registry:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including LYBALVI, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit <https://womensmentalhealth.org/research/pregnancyregistry/atypicalantipsychotic/>.

**Risk Summary:** Neonates exposed to antipsychotic drugs, including the olanzapine component of LYBALVI, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Overall published epidemiologic studies of pregnant women exposed to olanzapine have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are no available data on the use of samidorphan or the combination of olanzapine and samidorphan in pregnant women to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother associated with untreated schizophrenia or bipolar I disorder and with exposure to antipsychotics, including LYBALVI, during pregnancy.

##### LYBALVI

In an animal reproduction study, oral administration of olanzapine and samidorphan to pregnant rats during the period of organogenesis produced adverse effects on embryofetal development and fetal toxicity at maternally toxic doses that are 6 times and >400 times the maximum recommended human dose (MRHD) of 20 mg/10 mg olanzapine/samidorphan in LYBALVI, respectively based on AUC. There were no adverse effects on embryofetal development at doses of olanzapine and samidorphan that are approximately 1 and 80 times, respectively, the MRHD based on AUC.

##### Olanzapine

In animal reproduction studies, there was no evidence of malformations in rats or rabbits when orally administered olanzapine at doses up to 9 and 30 times the MRHD dose (20 mg) based on mg/m<sup>2</sup> body surface area, respectively. In an oral rat embryofetal developmental toxicity study, early resorptions and increased numbers of nonviable fetuses were observed at a dose 9 times the MRHD based on mg/m<sup>2</sup> body surface area and gestation was prolonged at 5 times the MRHD based on mg/m<sup>2</sup> body surface area. In an oral rabbit embryofetal developmental toxicity study, fetal toxicity (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic dose of olanzapine which is 30 times the MRHD based on mg/m<sup>2</sup> body surface area.

##### Samidorphan

In animal reproduction studies, oral administration of samidorphan to pregnant rats and rabbits during the period of organogenesis caused fetal toxicities in rats only at maternally toxic doses that are >248 times the human exposure at the MRHD of 10 mg/day based on AUC. Oral administration of samidorphan to pregnant rats during pregnancy and lactation resulted in lower pup survival and decreased pup weights at 188 times the human exposure at the MRHD based on AUC.

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

##### Clinical Considerations

###### Disease-Associated Maternal and/or Embryofetal Risk

There is risk to the mother from untreated schizophrenia or bipolar I disorder, including increased risk of relapse, hospitalization and suicide. Schizophrenia and bipolar I disorder are associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.

###### Fetal/Neonatal Risks

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs, including the olanzapine component of LYBALVI, during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.

###### Data

###### Human Data

Published data from observational studies, birth registries, and case reports on the use of atypical antipsychotics during pregnancy do not report a clear association with antipsychotics and major birth defects. A retrospective cohort study from a Medicaid database of 9258 women exposed to antipsychotics during pregnancy did not indicate an overall increased risk for major birth defects.

###### Animal Data

###### LYBALVI

Olanzapine and samidorphan were orally administered to pregnant rats during the period of organogenesis at doses of 0.5/10, 2/50, 6/200, and 0/200 mg/kg/day (olanzapine/samidorphan) which are approximately <1/10 times to 6/448 times the MRHD of 20 mg/10 mg, olanzapine/samidorphan, respectively, based on AUC. Maternal toxicity consisting of decreased body weight and food consumption was observed at all dose levels. Administration of samidorphan alone (200 mg/kg/day) and 6/200 mg/kg/day olanzapine/samidorphan decreased mean fetal body weights, increased litter incidence of bent ribs and bent scapula; however, the incidence of bent scapula and bent ribs was not increased when samidorphan was administered in combination with olanzapine compared to the incidence with samidorphan alone. Administration of olanzapine/samidorphan at 6/200 mg/kg/day also increased resorptions and post-implantation loss, with correlating lower mean viable fetuses and litter size. The no observed adverse effect level (NOAEL) for embryofetal development is 2/50 mg/kg/day, which is approximately 1/80 times the MRHD of 20 mg/10 mg olanzapine/samidorphan respectively, based on AUC.

### *Olanzapine*

Olanzapine was orally administered to pregnant rats and rabbits during the period of organogenesis at doses up to 18 mg/kg/day in rats and at doses up to 30 mg/kg/day in rabbits (9 times and 30 times the MRHD of 20 mg/day based on mg/m<sup>2</sup> body surface area, respectively), and no evidence of malformations was observed. In an oral rat embryofetal developmental toxicity study, early resorptions and increased numbers of nonviable fetuses were observed at a dose of 18 mg/kg/day (9 times the MRHD based on mg/m<sup>2</sup> body surface area). Gestation was prolonged at 10 mg/kg/day (5 times the MRHD based on mg/m<sup>2</sup> body surface area). In an oral rabbit embryofetal developmental toxicity study, fetal toxicity (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic dose of olanzapine at 30 mg/kg/day (30 times the MRHD based on mg/m<sup>2</sup> body surface area).

### *Samidorphan*

Samidorphan was orally administered to pregnant rats during the period of organogenesis at doses of 25, 100, and 300 mg/kg/day, which are approximately 29 to 742 times the MRHD of 10 mg/day based on AUC. Samidorphan was associated with an increased incidence of skeletal variations (unossified sternbrae and bent ribs) at maternally toxic doses of ≥100 mg/kg/day, and skeletal malformations (bent or misshapen forelimbs, hindlimbs, and/or scapula) at 300 mg/kg/day which are >248 and 742 times the MRHD based on AUC, respectively. The NOAEL for embryofetal development is 25 mg/kg/day, which is approximately 29 times the MRHD based on AUC.

Samidorphan did not cause adverse effects on embryofetal development when orally administered to pregnant rabbits during the period of organogenesis at doses of 10, 30, and 90 mg/kg/day, which are up to approximately 143 times the MRHD based on AUC.

Samidorphan was orally administered to pregnant rats during pregnancy and lactation at doses of 10, 30, or 100 mg/kg/day, which are approximately 7 to 188 times the MRHD based on AUC. Reduced pup survival, lower birth weights, and decreased pup body weight gains were observed at 100 mg/kg/day, which is 188 times the MRHD based on AUC. The NOAEL of 30 mg/kg/day is approximately 36 times the MRHD based on AUC. There were no adverse effects on pup developmental landmarks, learning, memory, reflexes, or fertility.

### **Lactation**

**Risk Summary:** Olanzapine is present in human milk. There are reports of excess sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements) in infants exposed to olanzapine through breast milk. There is no information on the effects of olanzapine on milk production. There are no data on the presence of samidorphan or the combination of olanzapine and samidorphan in human milk, the effects on the breastfed infant or the effects on milk production. When samidorphan was administered to lactating rats, samidorphan and a metabolite were detected in the plasma of nursing pups, likely due to the presence of samidorphan in milk. Infants exposed to LYBALVI should be monitored for excess sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements).

The development and health benefits of breastfeeding should be considered along with the mother's clinical need for LYBALVI and any potential adverse effects on the breastfed infant from LYBALVI or from the underlying maternal condition.

### **Females and Males of Reproductive Potential**

#### Fertility

##### *Females*

Based on the pharmacologic action of olanzapine (D2 antagonism), treatment with LYBALVI may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential.

**Pediatric Use:** The safety and effectiveness of LYBALVI have not been established in pediatric patients.

**Geriatric Use:** Clinical studies of LYBALVI did not include sufficient numbers of patients 65 years of age and older to determine whether they responded differently than younger adult patients.

**Olanzapine:** Of the 2,500 patients in premarketing clinical studies with orally administered olanzapine, 11% (263) were 65 years of age or over. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.

Studies in elderly patients with dementia-related psychosis have suggested that there may be a different tolerability profile in this population compared to younger patients with schizophrenia. Elderly patients with dementia-related psychosis treated with olanzapine are at an increased risk of death compared to placebo.

- In placebo-controlled studies of olanzapine in elderly patients with dementia-related psychosis, there was a higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in patients treated with olanzapine, compared to patients treated with placebo.
- In five placebo-controlled studies of olanzapine in elderly patients with dementia-related psychosis (n=1,184), the following adverse reactions were reported in olanzapine-treated patients at an incidence of at least 2% and

significantly greater than in placebo-treated patients: falls, somnolence, peripheral edema, abnormal gait, urinary incontinence, lethargy, increased weight, asthenia, pyrexia, pneumonia, dry mouth and visual hallucinations. The rate of discontinuation due to adverse reactions was greater with olanzapine than with placebo (13% vs 7%).

Consider a lower dosage of the olanzapine component of LYBALVI in geriatric patients who may have decreased clearance or an exaggerated pharmacodynamic response to olanzapine (e.g., oversedation).

**Hepatic Impairment:** Olanzapine and samidorphan plasma exposures were found to be higher in subjects with moderate hepatic impairment than in subjects with normal hepatic function. The effect of severe hepatic impairment was not studied. The higher plasma exposure in patients with moderate hepatic impairment was not expected to be clinically relevant. No dose adjustment of LYBALVI is needed in patients with hepatic impairment.

**Renal Impairment:** Plasma exposure to olanzapine and samidorphan was higher in patients with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>) compared to those with normal renal function. No dose adjustment of LYBALVI is needed in patients with mild (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup>), moderate (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), or severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>).

The effect of LYBALVI in patients with end-stage renal disorder was not studied. LYBALVI is not recommended for patients with end-stage renal disorder (eGFR of <15 mL/minute/1.73 m<sup>2</sup>).

### **OVERDOSAGE**

**Human Experience:** There is limited clinical experience with overdose with LYBALVI. In premarketing clinical trials of LYBALVI involving 861 patients, overdose of LYBALVI was identified in 7 patients. This included 4 patients with accidental overdose, 2 with intentional overdose, and 1 due to a medication administration error. None of the reported overdoses was associated with a fatal outcome. There was a reported ingestion of 11 tablets of LYBALVI 10 mg/10 mg (5.5 times and 11 times the maximum recommended daily dosage of the olanzapine and samidorphan components of LYBALVI, respectively). The patient was found unresponsive and admitted to the hospital. Medical treatment included fluids, electrolytes, a diuretic, and a detoxicant; the patient stabilized within 2 days.

In postmarketing reports of overdose with olanzapine, a component of LYBALVI, symptoms included agitation/aggressiveness, dysarthria, tachycardia, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. Less commonly reported symptoms include: aspiration, cardiopulmonary arrest, cardiac arrhythmias (such as supraventricular tachycardia and 1 patient experiencing sinus pause with spontaneous resumption of normal rhythm), delirium, possible neuroleptic malignant syndrome, respiratory depression/arrest, convulsion, hypertension, and hypotension. In 1 case of death, the amount of acutely ingested olanzapine was reported to be possibly as low as 450 mg; however, in another case, a patient was reported to survive an acute olanzapine ingestion of approximately 2,000 mg.

**Management of Overdose:** No specific antidotes for LYBALVI are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a certified Poison Control Center (1-800-222-1222) for additional overdose management recommendations.

**To report SUSPECTED ADVERSE REACTIONS, contact Alkermes, Inc. at 1-888-235-8008 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### **PATIENT COUNSELING INFORMATION**

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

This Brief Summary is based on LYBALVI full Prescribing Information (revised: May 2021).

Distributed by:  
Alkermes, Inc.  
852 Winter Street  
Waltham, MA 02451-1420













©2021 Alkermes, Inc. All rights reserved. LYB-001034 Printed in the U.S.A.

ALKERMES® is a registered trademark of Alkermes, Inc. LYBALVI® is a registered trademark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc., under license.

# PSYCHIATRYonline

Your Destination for Lifelong Learning in Psychiatry

The one-stop resource for information on diagnosis, treatment, guidelines, the latest research, and breaking news from the field.



**PsychiatryOnline.org** is the platform for all American Psychiatric Association Publishing journals, *DSM-5-TR™*, and bestselling textbooks, as well as APA Practice Guidelines, and continuing medical education.

This is a one-stop resource for information on psychiatric diagnosis, treatment, guidelines, the latest research, and breaking news from the field. From a single location, users can search across all books and journals to find the most relevant content easier than ever.

Subscribe to products individually or to the DSM Select package that includes the DSM-5® library, books and select journals.

**Go to [www.appi.org](http://www.appi.org) to subscribe.**

*Institutional subscription options are available.*

For more information contact: [institutions@psych.org](mailto:institutions@psych.org);  
800-368-5777 ext. 3729



[psychiatryonline.org](http://psychiatryonline.org)



# THE AMERICAN PSYCHIATRIC ASSOCIATION

800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024

(888) 357-7924 (toll-free inside the U.S. and Canada)

web site: [www.psychiatry.org](http://www.psychiatry.org) • e-mail: [apa@psych.org](mailto:apa@psych.org)

## Chairpersons of Councils, Committees, and Task Forces

### Standing Committees

<b>Bylaws</b>	Edward R. Herman, J.D., M.D.
<b>Elections</b>	Josepha A. Cheong, M.D.
<b>Ethics</b>	Charles Dike, M.D.
<b>Finance and Budget</b>	Ann T. Sullivan, M.D.
<i>Audit</i>	Richard F. Summers, M.D.
<i>Investment Oversight</i>	Steven S. Sharfstein, M.D.
<b>Joint Reference</b>	Petros Levounis, M.D., M.A.
<b>Membership</b>	Gail Robinson, M.D.
<b>Nominating</b>	Vivian B. Pender, M.D.
<b>Tellers</b>	Mariam F. Aboukar, D.O.

### Non-Standing Committee

<b>Conflict of Interest</b>	Sandra M. DeJong, M.D., M.Sc.
-----------------------------	-------------------------------

### Councils

#### Council on Addiction Psychiatry

Smita Das, M.D., M.P.H., Ph.D.

#### Council on Advocacy and Government Relations

Katherine G. Kennedy, M.D.

*Advocacy and Litigation Funding*

Patrick Aquino, M.D.

#### Council on Children, Adolescents, and Their Families

Anish R. Dube, M.D., M.P.H.

*Women's Mental Health*

Ludmila B. De Faria, M.D.

#### Council on Communications

Howard Liu, M.D., M.B.A.

#### Council on Consultation-Liaison Psychiatry

Maria L. Tiamson-Kassab, M.D.

#### Council on Geriatric Psychiatry

Maria D. Llorente, M.D.

#### Council on Healthcare Systems and Financing

Robert L. Trestman, M.D., Ph.D.

*Integrated Care*

Benjamin G. Druss, M.D.

*RBRVS, Codes and Reimbursement*

Jeremy S. Musher, M.D.

*Reimbursement for Psychiatric Care*

Brian Hepburn, M.D.

*Telepsychiatry*

Shabana Khan, M.D.

#### Council on International Psychiatry and Global Health

Pamela Collins, M.D., M.P.H.

#### Council on Medical Education and Lifelong Learning

Art Walaszek, M.D.

*Innovation*

Steven Chan, M.D., M.B.A.

*Scientific Program*

Eric Williams, M.D.

*Scientific Program—Mental Health Services Conference*  
*(Oct. to Oct. tenure)*

John Santopietro, M.D.

*Vestermark Award Committee*

Donna M. Sudak, M.D.

*Well-being and Burnout*

Uchenna Okoye, M.D., M.P.H.

#### Council on Minority Mental Health and Health Disparities

Walter Wilson, Jr., M.D.

#### Council on Psychiatry and Law

Richard Martinez, M.D., M.H.

*Judicial Action*

Reena Kapoor, M.D.

#### Council on Quality Care

Carol L. Alter, M.D.

*Mental Health Information Technology*

John Torous, M.D.

*Quality and Performance Measurement*

David S. Kroll, M.D.

*Practice Guidelines*

Daniel J. Anzia, M.D.

#### Council on Research

Jonathan E. Alpert, M.D., Ph.D.

*Climate Change and Mental Health*

Elizabeth Haase, M.D.

*Psychiatric Dimensions of Disasters*

Joshua C. Morganstein, M.D.

# Acadia is a leading provider of behavioral healthcare services across the United States.

Join our network of physicians & midlevel providers

## TREATMENT NETWORK:

225+ Locations | 10,000+ Beds | 40 States | 20,000+ Employees | 70,000+ Patients Treated Daily  
Inpatient Treatment Programs | Residential Programs | Outpatient – Comprehensive Treatment Centers


We are recruiting for full- and part-time psychiatrists across the country. To learn more about our psychiatry and addiction medicine opportunities, scan the QR code or contact our physician recruiters below:

**Debbie Hughes:** [Debbie.Hughes@acadiahealthcare.com](mailto:Debbie.Hughes@acadiahealthcare.com)

**Andy Diffenbaugh:** [Andy.Diffenbaugh@acadiahealthcare.com](mailto:Andy.Diffenbaugh@acadiahealthcare.com)



## NEW TITLES in PSYCHIATRY



### Late-Life Depression and Anxiety

Edited by Art Walaszek, M.D.


2022 • 376 pages • ISBN 978-1-61537-347-5 • Paperback • \$69.00 • Item #37347  
2022 • 376 pages • ISBN 978-1-61537-441-0 • eBook • \$55.00 • Item #37441



### Textbook of Autism Spectrum Disorders, Second Edition

Edited by Eric Hollander, M.D., Randi Hagerman, M.D., and Casara Ferretti, M.S.


2022 • 752 pages • ISBN 978-1-61537-304-8 • Hardcover • \$115.00 • Item #37304  
2022 • 752 pages • ISBN 978-1-61537-421-2 • eBook • \$85.00 • Item #37421



### Textbook of Women's Reproductive Mental Health

Edited by Lucy A. Hutner, M.D., Lisa A. Catapano, M.D., Ph.D., Sarah M. Nagle-Yang, M.D., Katherine E. Williams, M.D., and Lauren M. Osborne, M.D.


2022 • 784 pages • ISBN 978-1-61537-306-2 • Hardcover • \$135.00 • Item #37306  
2022 • 784 pages • ISBN 978-1-61537-386-4 • eBook • \$108.00 • Item #37386



### Thinking About Prescribing The Psychology of Psychopharmacology With Diverse Youth and Families

Edited by Shashank V. Joshi, M.D., FAAP, DFAACAP, and Andrés Martin, M.D., M.P.H.

2022 • 395 pages • ISBN 978-1-61537-388-8 • Paperback • \$65.00 • Item #37388  
2022 • 395 pages • ISBN 978-1-61537-389-5 • eBook • \$52.00 • Item #37389



### Psychodynamic Psychopharmacology Caring for the Treatment-Resistant Patient

David Mintz, M.D.

2022 • 295 pages • ISBN 978-1-61537-152-5 • Paperback • \$62.00 • Item #37152  
2022 • 295 pages • ISBN 978-1-61537-400-7 • eBook • \$49.95 • Item #37400



### Geriatric Mental Health Care Lessons from a Pandemic

Edited by Robert P. Roca, M.D., M.P.H., Micheline Dugue, M.D., and Maria Llorente, M.D., FAPA

2022 • 384 pages • ISBN 978-1-61537-465-6 • Paperback • \$58.00 • Item #37465  
2022 • 384 pages • ISBN 978-1-61537-466-3 • eBook • \$46.50 • Item #37466



# Go Online

Visit [ajp.psychiatryonline.org](http://ajp.psychiatryonline.org) for these features!

## AJP in Advance

*Discover the latest research advances before they appear in print*

### **A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial**

Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. This study tested whether automated self-association training—a brief, noninvasive, computer-based intervention—could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response.

## AJP Audio and Video

In the November episode of AJP Audio, Antonia V. Seligowski, Ph.D., discusses how significant genetic correlations were identified between PTSD and cardiovascular disease as well as support for a causal link from PTSD to hypertension and coronary artery disease (Seligowski et al., p. 814).

In November's video highlights, AJP Deputy Editor Danny Pine, M.D., discusses the articles "Charting the Landscape of Genetic Overlap Between Mental Disorders and Related Traits Beyond Genetic Correlation" (Hindley et al., p. 833) and "Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder" (Brownstein et al., p. 853).

## AJP CME

You can earn CME credits by reading articles in *The American Journal of Psychiatry*. Three articles in this issue form a short course that consists of reading the article and answering three multiple-choice questions with a single correct answer for up to 1 AMA PRA Category 1 Credit™ each. Credit is issued only to subscribers of the online AJP CME Course Program.

See the list below for articles in this month's issue that are the subject of a CME quiz.

### **In this issue**

---

Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition (Hagman et al., p. 807)

---

Leveraging Large-Scale Genetics of PTSD and Cardiovascular Disease to Demonstrate Robust Shared Risk and Improve Risk Prediction Accuracy (Seligowski et al., p. 814)

---

Association Between Polygenic Risk Scores and Outcome of ECT (Sigström et al., p. 844)

---

@APAPubJournals



Psychiatry Online



AMERICAN  
PSYCHIATRIC  
ASSOCIATION  
PUBLISHING



[www.appi.org](http://www.appi.org)  
1-800-368-5777  
[appi@psych.org](mailto:appi@psych.org)